Table 3.
Influence of Several Variables on the Outcome of Graves' Ophthalmopathy in 65 Untreated Patients
| Improved | Stable | Worsened | p | ||
|---|---|---|---|---|---|
| Age |
|
40.7±15.3 |
42.2±13 |
48.2±15.3 |
0.37a |
| Sex |
Males |
10/19 (52.6%) |
7/19 (36.8%) |
2/19 (10.5%) |
0.77b |
| |
Females |
23/46 (50%) |
15/47 (31.9%) |
8/47 (17%) |
|
| Smoking* |
Non-smokers |
16/26 (61.5%) |
8/26 (30.7%) |
2/26 (7.6%) |
0.32b |
| |
Ex-smokers |
4/9 (44.4%) |
2/9 (22.2%) |
3/9 (33.3%) |
|
| |
Smokers |
13/30 (43.3%) |
12/30 (40%) |
5/30 (16.6%) |
|
| |
Pack years |
0.4 (IQR: 0–7.2) |
0.2 (IQR: 0–8.4) |
4.8 (IQR: 1.1–9.8) |
0.46c |
| Smoking† |
Non-smokers |
16/26 (61.5%) |
8/26 (30.7%) |
2/26 (7.6%) |
0.50b |
| |
Ex-smokers |
6/16 (37.5%) |
6/16 (37.5%) |
4/16 (25%) |
|
| |
Smokers |
11/23 (47.8%) |
8/23 (34.7%) |
4/23 (17.3%) |
|
| |
Pack years |
0.9 (IQR: 0–9.7) |
1.1 (IQR: 0–9) |
3.8 (IQR: 0.2–11.2) |
0.58c |
| GO duration† |
|
42 months (IQR: 16.2–73.7) |
29 months (IQR: 21–72) |
45 months (IQR: 33–81) |
0.72c |
| TD duration† |
|
46 months (IQR: 19.7–100.2) |
49 months (IQR: 21–83) |
79.5 months (IQR: 43–140) |
0.36c |
| Thyroid treatment† |
None |
1/4 (25%) |
2/4 (50%) |
1/4 (25%) |
0.19b |
| |
MMI |
5/17 (29.4%) |
9/17 (52.9%) |
3/17 (17.6%) |
|
| |
RI |
6/11 (54.5%) |
5/11 (45.4%) |
0/11 (0%) |
|
| |
TX |
17/28 (60.7%) |
6/28 (21.4%) |
5/28 (17.8%) |
|
| |
LT4 |
4/5 (80%) |
0/5 (0%) |
1/5 (0%) |
|
| Thyroid status* |
Hyperthyroid |
7/13 (53.8%) |
4/13 (30.7%) |
2/13 (15.3%) |
0.78b |
| |
Euthyroid |
25/50 (50%) |
16/50 (32%) |
8/50 (16%) |
|
| |
Hypothyroid |
1/2 (50%) |
2/2 (100%) |
0/2 (0%) |
|
| Thyroid status† |
Hyperthyroid |
0/0 (0%) |
0/0 (0%) |
0/0 (0%) |
0.78b |
| |
Euthyroid |
32/63 (50.7%) |
21/63 (33.3%) |
10/63 (15.8%) |
|
| |
Hypothyroid |
1/2 (50%) |
1/2 (50%) |
0/2 (0%) |
|
| Thyroid volume* |
|
27 mL (IQR: 11.2–36.7) |
17.5 mL (IQR: 12–29) |
28 mL (IQR: 21–33.5) |
0.54c |
| TRAb* |
|
8.4 U/L (IQR: 3.3–26.3) |
3.5 U/L (IQR: 1.6–9.9) |
4.2 U/L (IQR: 1.3–15) |
0.08c |
| TRAb† |
|
3.9 U/L (IQR: 0–9.2) |
1.6 U/L (IQR: 0–5.3) |
4 U/L (IQR: 1–9.8) |
0.44c |
| TRAb reduction | 7 U/L (IQR: 2.2–14.3) | 1.8 U/L (IQR: −0.7–3.2) | 4.2 U/L (IQR: −5–22.9) | 0.07c |
LT4 refers only to patients given the medication for primary hypothyroidism. p-Values were obtained by: aANOVA, bFisher's exact test, and cKruskal–Wallis, as indicated.
*
First observation; †last observation.